484 related articles for article (PubMed ID: 33069895)
1. Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy.
Li Y; Gao Y; Zhang X; Guo H; Gao H
Int J Pharm; 2020 Dec; 591():119986. PubMed ID: 33069895
[TBL] [Abstract][Full Text] [Related]
2. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
[TBL] [Abstract][Full Text] [Related]
3. Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes.
Corradetti B; Pisano S; Conlan RS; Ferrari M
J Pharmacol Exp Ther; 2019 Sep; 370(3):636-646. PubMed ID: 30737357
[TBL] [Abstract][Full Text] [Related]
4. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.
Lim S; Park J; Shim MK; Um W; Yoon HY; Ryu JH; Lim DK; Kim K
Theranostics; 2019; 9(25):7906-7923. PubMed ID: 31695807
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology Approaches to Improving Cancer Immunotherapy.
Hagan CT; Medik YB; Wang AZ
Adv Cancer Res; 2018; 139():35-56. PubMed ID: 29941106
[TBL] [Abstract][Full Text] [Related]
6. Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy.
Peng H; He X; Wang Q
Front Immunol; 2022; 13():1035997. PubMed ID: 36405688
[TBL] [Abstract][Full Text] [Related]
7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
8. Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer.
Abujamous L; Soltani A; Al-Thawadi H; Agouni A
Biomol Biomed; 2024 Mar; 24(2):230-237. PubMed ID: 38231530
[TBL] [Abstract][Full Text] [Related]
9. Natural product-based nanoformulations for cancer therapy: Opportunities and challenges.
Kashyap D; Tuli HS; Yerer MB; Sharma A; Sak K; Srivastava S; Pandey A; Garg VK; Sethi G; Bishayee A
Semin Cancer Biol; 2021 Feb; 69():5-23. PubMed ID: 31421264
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnological approaches for diagnosis and treatment of ovarian cancer: a review of recent trends.
Ding H; Zhang J; Zhang F; Xu Y; Liang W; Yu Y
Drug Deliv; 2022 Dec; 29(1):3218-3232. PubMed ID: 36259505
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology in ovarian cancer: Diagnosis and treatment.
Barani M; Bilal M; Sabir F; Rahdar A; Kyzas GZ
Life Sci; 2021 Feb; 266():118914. PubMed ID: 33340527
[TBL] [Abstract][Full Text] [Related]
12. Targeted Nanoparticle Drug Delivery System for the Enhancement of Cancer Immunotherapy.
Zhang H; Wu Y; Hu Y; Li X; Zhao M; Lv Z
J Biomed Nanotechnol; 2019 Sep; 15(9):1839-1866. PubMed ID: 31387674
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in drug delivery strategies for treatment of ovarian cancer.
Zahedi P; Yoganathan R; Piquette-Miller M; Allen C
Expert Opin Drug Deliv; 2012 May; 9(5):567-83. PubMed ID: 22452661
[TBL] [Abstract][Full Text] [Related]
14. Cell membrane coated nanoparticles as a biomimetic drug delivery platform for enhancing cancer immunotherapy.
Zhong Z; Deng W; Wu J; Shang H; Tong Y; He Y; Huang Q; Ba X; Chen Z; Tang K
Nanoscale; 2024 May; 16(18):8708-8738. PubMed ID: 38634521
[TBL] [Abstract][Full Text] [Related]
15. Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article.
Khalifa AM; Elsheikh MA; Khalifa AM; Elnaggar YSR
J Control Release; 2019 Oct; 311-312():125-137. PubMed ID: 31476342
[TBL] [Abstract][Full Text] [Related]
16. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery.
Kyu Shim M; Yang S; Sun IC; Kim K
Adv Drug Deliv Rev; 2022 Apr; 183():114177. PubMed ID: 35245568
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.
Grimaldi AM; Incoronato M; Salvatore M; Soricelli A
Nanomedicine (Lond); 2017 Oct; 12(19):2349-2365. PubMed ID: 28868980
[TBL] [Abstract][Full Text] [Related]
18. Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer.
Rhoda K; Choonara YE; Kumar P; Bijukumar D; du Toit LC; Pillay V
Expert Opin Drug Deliv; 2015 Apr; 12(4):613-34. PubMed ID: 25300775
[TBL] [Abstract][Full Text] [Related]
19. A Comprehensive Review on Current Treatments and Challenges Involved in the Treatment of Ovarian Cancer.
Saman S; Srivastava N; Yasir M; Chauhan I
Curr Cancer Drug Targets; 2024; 24(2):142-166. PubMed ID: 37642226
[TBL] [Abstract][Full Text] [Related]
20. Integrating natural compounds and nanoparticle-based drug delivery systems: A novel strategy for enhanced efficacy and selectivity in cancer therapy.
Manzari-Tavakoli A; Babajani A; Tavakoli MM; Safaeinejad F; Jafari A
Cancer Med; 2024 Mar; 13(5):e7010. PubMed ID: 38491817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
